Limitations of applying summary results of clinical trials to individual patients: The need for risk stratification

JAMA

Volumn 298, Issue 10, 2007, Pages 1209-1212

  Kent, David M ^a   Hayward, Rodney A ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HIGH RISK POPULATION; HUMAN; METHODOLOGY; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; ARTICLE; EPIDEMIOLOGY; RISK; STATISTICAL ANALYSIS; STATISTICS; TREATMENT OUTCOME;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; HUMANS; RISK; TREATMENT OUTCOME;

EID: 34548575455     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.10.1209     Document Type: Note

References (22)

1. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet. 1995;345(8965):1616-1619.
2. Vijan S, Kent DM, Hayward RA. Are randomized controlled trials sufficient evidence to guide clinical practice in type 2 (non-insulin dependent) diabetes mellitus? Diabetologia. 2000;43(1):125-130.
3. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment-effects, and the trouble with averages. Milbank Q. 2004;82(4):661-687.
4. Hayward RA, Kent DM, Vijan S, Hofer TP. Reporting clinical trial results to inform providers, payers, and consumers. Health Aff (Millwood). 2005;24(6):1571-1581.
5. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis) uses of baseline data in clinical trials. Lancet. 2000;355(9209):1064-1069.
6. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992;116(1):78-84.
7. Rothwell PM. Treating individuals 2: subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365(9454):176-186.
8. Hayward RA, Kent DM, Vijan S, Hofer TP. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol. 2006;6:18.
9. UKDPS Risk Engine. The Oxford Centre for Diabetes, Endocrinlogy & Metabolism. Diabetes Trial Unit Web site. http://www.dtu.ox.ac.uk/index.php? maindoc=/riskengine/. Accessed Februrary 5, 2007.
10. Selker HP, Griffith JL, Beshansky JR, et al. Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. Ann Intern Med. 1997;127(7):538-548.
11. Rothwell PM, Mehta Z, Howard SC, Gutnikov SA, Warlow CP. Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet. 2005;365(9455):256-265.
12. Ioannidis JP, Lau J. Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm. Am J Epidemiol. 1998;148(11):1117-1126.
13. Kent DM, Hayward RA, Griffith JL, et al. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med. 2002;113(2):104-111.
14. Kent DM, Ruthazer R, Griffith JL, et al. Comparison of mortality benefit of immediate thrombolytic therapy versus delayed primary angioplasty. Am J Cardiol. 2007;99(10):1384-1388.
15. Kent DM, Jafar TH, Hayward RA, et al. Progression risk, urinary protein excretion and the treatment-effects of angiotensin converting enzyme inhibitors in non-diabetic nephropathy. J Am Soc Nephrol. 2007;18(6):1959-1965.
16. Ioannidis JP, Lau J. The impact of high-risk patients on the results of clinical trials. J Clin Epidemiol. 1997;50(10):1089-1098.
17. Rothwell PM, Warlow CP. Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists' Collaborative Group. Lancet. 1999;353(9170):2105-2110.
18. Food and Drug Administration. Xigris: drotrecogin alfa (activated): PV 3420 AMP. Indianapolis, IN: Eli Lilly & Co; 2001. http://www.fda.gov/cder/ foi/label/2001/droteli112101LB.pdf. Accessibility verified August 9, 2007.
19. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835-842.
20. Morrow DA, Antman EM, Snapinn SM, et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST-elevation acute coronary syndromes: application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J. 2002;23(3):223-229.
21. Kent DM, Ruthazer R, Selker HP. Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset? Stroke. 2003;34(2):464-467.
22. Thune JJ, Hoefsten DE, Lindholm MG, et al. Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty. Circulation. 2005;112(13):2017-2021.